课题基金 / 基金详情

1H NMR STUDIES OF NON-HODGKINS LYMPHOMA

1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
非霍奇金淋巴瘤的 1H NMR 研究
批准号:
7656108
负责人:
JERRY D GLICKSON
金额:
$35.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-03-01 至 2013-01-31

项目摘要

项目成果

JERRY D GLICKSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):该项目的长期目标是开发用于预测和检测非霍奇金淋巴瘤(NHL)治疗反应的1H MRS和MRI方法。非霍奇金淋巴瘤是一种常见的恶性肿瘤,自1950年以来其发病率增加了90%以上,在总体经济影响中排名第四。PI参与的一项多机构临床研究已经证明,31P MRS可以预测大约2/3未能表现出完全临床反应的肿瘤,但该方法仅限于相对较大的浅表肿瘤。我们的方法是开发质子成像和光谱分析方法,能够早期检测所有患者的反应。在这笔赠款的第一个资助周期中,我们研究了弥漫性大B细胞淋巴瘤(DLBCL)的异种移植模型DLCL2,这是最常见的非霍奇金淋巴瘤,影响了大约三分之一的患者。我们已经评估了1H MRS测量总胆碱和乳酸以及1H MRI(扩散加权和T2加权,动态对比增强和T1a加权)在该肿瘤中的应用。我们研究了多种临床相关疗法的疗效,包括:环磷酰胺、羟基阿霉素、长春新碱和强的松联合化疗(CHOP)、CHOP加Bryostatin 1(CHOPB)、单用Rituximab、Rituximab加CHOP和放射治疗。这些研究获得的最令人兴奋的结果是:1)在CHOP的一个周期内检测到的乳酸显著减少,这与肿瘤增殖减少相关;2)表观扩散常数和T2的局部变化,对应于肿瘤中的反应区域;3)设计和实现了一种新型的混合脉冲序列,用于乳酸的1H成像,该序列利用多层阿达玛空间编码和通过选择性多量子相干转移进行的化学位移成像。这个序列是在动物扫描仪上开发的,现在已经被翻译成临床扫描仪,并应用于一名NHL患者。目前建议的目标是1)确定治疗相关乳酸减少的潜在机制,2)确定导致MRI检测到的肿瘤局部反应的机制,3)将研究扩展到反应更敏感的DLBCL异种移植模型和滤泡性淋巴瘤,滤泡性淋巴瘤是NHL的下一种最常见形式。我们将使用一系列先进和创新的方法来实现这些目标,包括1)使用两室模型来区分由于糖酵解和洗脱的变化而导致的稳态乳酸浓度的变化,2)确定FDG-PET成像和DCE MRI是否可以区分由于糖酵解速率的变化或由于乳酸消除速率的变化而引起的乳酸水平的变化,3)17O成像方法同时成像血流和氧气消耗,以及4)通过预测和实验的氧耗速率验证13C核磁共振的代谢网络模型。我们还将深入探讨有助于肿瘤局部治疗反应的可能机制。公共卫生相关性:该项目旨在开发核磁共振方法来预测和早期检测非霍奇金淋巴瘤(NHL)患者的治疗反应,非霍奇金淋巴瘤是人类癌症的流行形式之一。我们参与的一个临床项目已经开发出一种31P核磁共振方法,可以预测大约2/3的肿瘤对常规治疗无效。然而,这种方法仅限于有较大表浅肿瘤的患者。在这里,我们正在开发更灵敏的核磁共振方法,可以用来早期检测所有NHL患者的反应。同样的方法也应该适用于其他流行形式的人类癌症。
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop 1H MRS and MRI methods for prediction and detection of therapeutic response of non-Hodgkin's lymphoma (NHL), a prevalent malignancy whose incidence has increased by more than 90% since 1950 that ranks fourth in overall economic impact. A multi-institutional clinical study in which the PI is participating has already demonstrated that 31P MRS can predict about 2/3 of the tumors that fail to exhibit a complete clinical response, but this method is limited to relatively large superficial tumors. Our approach has been to develop proton imaging and spectroscopy methods that are capable of early detection of response in all patients. During the first funding cycle of this grant we examined a xenograft model, DLCL2, of diffuse large B-cell lymphoma (DLBCL), the most common form of NHL affecting about 1/3 of all patients. We have evaluated the utility of 1H MRS measurements of total choline and lactate and 1H MRI (diffusion-weighted and T2-weighted with dynamic contrast-enhanced and T1A-weighted) in this tumor. We have examined the response to multiple clinically relevant therapies including: combination chemotherapy with Cyclophosphamide, Hydroxydoxorubicin, Oncovin and Prednisone (CHOP), CHOP plus Bryostatin 1 (CHOPB), Rituximab alone, Rituximab plus CHOP and radiation therapy. The most exciting results from these studies are: 1) significant decreases in lactate detected within one cycle of CHOP that correlated with decreased tumor proliferation; 2) regional changes in the apparent diffusion constant and in T2 corresponding to areas of response in the tumor; 3) design and implementation of a novel hybrid pulse sequence for 1H imaging of lactate utilizing multi-slice Hadamard spatial encoding and chemical shift imaging via a selective multi-quantum coherence transfer. This sequence was developed on the animal scanner and has now been translated to a clinical scanner and applied to an NHL patient. The objectives of the current proposal are 1) to define the mechanisms underlying therapy associated decreases in lactic acid, 2) to define the mechanism leading to MRI-detected regional response of the tumor, and 3) to extend the study to more responsive DLBCL xenograft models and to follicular lymphoma, the next most common form of NHL. We will employ a number of sophisticated and innovative methods to achieve these goals including 1) use of a two- compartment model to distinguish between changes in steady-state lactate concentration due to changes in glycolysis and washout, 2) determination if FDG-PET imaging and DCE MRI, which are more readily available in the clinic than 13C MRS, can distinguish between changed in lactate levels due to alterations in glycolytic rate or due to a change in the rate of lactate elimination, 3) 17O imaging methods to image perfusion and oxygen consumption simultaneously and 4) validation of a metabolic network model for 13C NMR by predicted and experimental oxygen consumption rates. We will also explore in depth possible mechanisms that could contribute to regional therapeutic response in the tumor. PUBLIC HEALTH RELEVANCE: This project is directed towards developing NMR methods for prediction and early detection of therapeutic response of individual patients with non-Hodgkin's lymphoma (NHL), one of the prevalent forms of human cancer. A clinical program in which we participate has already developed a 31P NMR method for predicting about 2/3 of the tumors that will fail to respond to conventional treatment. This method, however, is limited to patients with large superficial tumors. Here we are developing much more sensitive 1H NMR methods that can be used for early detection of response in all NHL patients. The same methods should be applicable to other prevalent forms of human cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic Imaging of Targeted Therapies in Cancer
  • 批准号:
    10551887
  • 项目类别:
  • 资助金额:
    $59.77万
  • 财政年份:
    2022
  • 负责人:
    JERRY D GLICKSON
  • 依托单位:
Metabolic Imaging of Targeted Therapies in Cancer
  • 批准号:
    10391657
  • 项目类别:
  • 资助金额:
    $62.55万
  • 财政年份:
    2022
  • 负责人:
    JERRY D GLICKSON
  • 依托单位:
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition
  • 批准号:
    10362649
  • 项目类别:
  • 资助金额:
    $49.22万
  • 财政年份:
    2020
  • 负责人:
    JERRY D GLICKSON
  • 依托单位:
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition
  • 批准号:
    10580590
  • 项目类别:
  • 资助金额:
    $49.22万
  • 财政年份:
    2020
  • 负责人:
    JERRY D GLICKSON
  • 依托单位:
海外基金